| 付余,
，聂昊,
，毛如雪,
，郑凯,.特拉唑嗪：通过调节磷酸甘油酸酯激酶1防治帕金森病[J].神经损伤功能重建,2024,(4):242-246 |
| 特拉唑嗪：通过调节磷酸甘油酸酯激酶1防治帕金森病 |
| Terazosin: A potential Method of Treatment and Prevention of Parkinson’s Disease throughPhosphoglycerate Kinase1 |
| |
| DOI： |
| 中文关键词: 特拉唑嗪 帕金森病 磷酸甘油酸酯激酶1 |
| 英文关键词: Terazosin Parkinson’s disease phosphoglycerate kinase1 |
| 基金项目:国家自然科学基
金（丰富环境通
过 DNA 甲 基 化
调控Foxd3/miR-
135a-5p 通 路 改
善 AD 小鼠学习
记 忆 的 机 制 研
究，No. 8237144
2） |
|
| 摘要点击次数: 1156 |
| 全文下载次数: 1933 |
| 中文摘要: |
| 特拉唑嗪（terazosin，TZ）作为哌唑嗪的衍生物，是长效选择性α1肾上腺受体阻滞剂，因其水溶性好，生
物利用度高，半衰期长，在临床上广泛运用于高血压和良性前列腺增生的治疗。近期研究发现，TZ在特定剂
量范围时能激活细胞内的磷酸甘油酸酯激酶 1（Phosphoglycerate kinase1，Pgk1）保护神经细胞、防治帕金森
病，该作用可能与其通过激活Pgk1改善细胞能量代谢、提高细胞内三磷酸腺苷浓度和激活热休克蛋白90相
关。这提示特拉唑嗪类药物新的临床应用前景。本文将就TZ新发现的药理机制和潜在的临床运用前景等方
面的研究进展进行回顾和总结，并探讨未来可能的研究方向。 |
| 英文摘要: |
| Terazosin, as a derivative of prazosin, is a long-acting selective α1 adrenal receptor blocker, which is
widely used in the treatment of hypertension and benign prostatic hyperplasia due to its good water solubility, high
bioavailability and long half-life. Recent studies have found that TZ can activate intracellular phosphoglycerate
kinase1(Pgk1) in a specific dose range to protect the neurons and may be beneficial for the treatment and
prevention of Parkinson’s disease (PD). This effect may be related to the improvement of cell energy metabolism,
the increase of intracellular ATP concentration and the activation of Hsp90 caused by the activation of Pgk1. This
indicates a new clinical application prospect of terazosin. This article will review and summarize the research
progress of TZ in the newly discovered pharmacological mechanism and potential clinical application prospect,
and discuss the possible research direction in the future. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |